Humacyte Anticipates Q1 Earnings Announcement
| HUMA Stock | USD 2.26 0.02 0.88% |
About 54% of Humacyte's investor base is interested to short. The analysis of overall sentiment of trading Humacyte stock suggests that many investors are impartial at this time. The current market sentiment, together with Humacyte's historical and current headlines, can help investors time the market. In addition, many technical investors use Humacyte stock news signals to limit their universe of possible portfolio assets.
Summary Humacyte is gearing up to release its first-quarter earnings on May 13th, anticipating improved EPS results. Analysts set an average pric
Read at gurufocus.com
 |
Humacyte Fundamental Analysis
We analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Humacyte is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Humacyte Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Humacyte stock to make a market-neutral strategy. Peer analysis of Humacyte could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics with similar companies.
Peers
Humacyte Related Equities
| COGT | Cogent Biosciences | 5.70 | ||||
| GLUE | Monte Rosa | 1.88 | ||||
| KNSA | Kiniksa Pharmaceuticals | 0.36 | ||||
| ABSI | Absci Corp | 1.34 | ||||
| QSI | QuantumSi | 1.37 | ||||
| NAUT | Nautilus Biotechnology | 2.63 | ||||
| CRBU | Caribou Biosciences | 2.86 | ||||
| IDYA | Ideaya Biosciences | 3.52 | ||||
| HUMAW | Humacyte | 5.77 |
Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |